Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.

Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation

Chen Y-L. et al, (2020), The Journal of Experimental Medicine, 217

Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells.

Luo J. et al, (2019), The Journal of allergy and clinical immunology, 144, 1722 - 1726.e10

Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis

Chen Y-L. et al, (2019), Science Translational Medicine, 11, eaax2945 - eaax2945

Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.

Hardman C. et al, (2019), The Journal of allergy and clinical immunology, 143, 2329 - 2333

CD1a presentation of endogenous antigens by group 2 innate lymphoid cells

Hardman CS. et al, (2017), Science Immunology, 2, eaan5918 - eaan5918